$OPTU

Top insider buys and sells from Friday’s market activity

On August 28, 2026, notable insider trading included Optimum Communications (OPTU) director Neil S. Subin buying $2.45M in shares, REGENXBIO (RGNX) director Gregory Austin Ciongoli purchasing $949K, and Pulse Biosciences (PLSE) COO Liane Rae Teplitsky acquiring $99K. United States Antimony (UAMY) CEO Gary C. Evans bought $98K in shares, while Battalion Oil (BATL) director William D. Rogers purchased $91K. On the sell side, Life Time Group (LTH) insiders sold $126M, Relay Therapeutics (RLAY) 10%

Original reporting
Published Aug 31, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 1:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$OPTU
Bullish
medium confidence
Mentioned
$OPTU · $RGNX · $PLSE · $UAMY · $BATL · $LTH
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$OPTUBullishLow
01

Why it matters

Provides traders with direct insight into insider sentiment, which can be a leading indicator for short‑term price moves.

02

Market read

Insider activity across these tickers may influence short‑term trading decisions, especially for the larger transactions in LTH, RLAY, and SNOW.

03

What to watch

Potential hidden strategic moves or upcoming financing not disclosed.

Relevance 4/10Novelty 3/10Timing: insider filings disclosed August 28, 2026

Background

The article aggregates recent Form 4 insider transactions across several U.S. listed companies.

Company-level read

Ticker impact

$OPTUBullishMedium confidence
Context

Director Neil S. Subin bought $2.45M of OPTU shares, indicating insider confidence despite a 20% weekly surge.

Expected impact

Modest upside if buying pressure continues.

Evidence & confidence

Insider purchase size relative to float suggests belief in near-term performance.

$RGNXBullishLow confidence
Context

Director Gregory Austin Ciongoli purchased $949k of RGNX stock, showing belief in the biotech despite a 13% weekly decline.

Expected impact

Limited upside unless broader biotech sentiment improves.

Evidence & confidence

Purchase size modest; market already discounting.

$PLSENeutralLow confidence
Context

COO Liane Rae Teplitsky bought $99,965 of PLSE shares near its 52‑week high, indicating insider support.

Expected impact

Potential stabilization rather than strong rally.

Evidence & confidence

Purchase small relative to market cap; stock already near peak.

$UAMYBullishLow confidence
Context

CEO Gary C. Evans bought 20,000 UAMY shares for $98,400, a modest stake increase amid a 46% six‑month decline.

Expected impact

Possible modest upside if market perceives buy‑back support.

Evidence & confidence

Purchase size small; broader commodity exposure dominates.

$BATLBullishLow confidence
Context

Director William D. Rogers acquired 70,000 BATL shares for $91,168 while the stock sits near its 52‑week low.

Expected impact

Limited upside unless oil sector improves.

Evidence & confidence

Purchase modest; sector fundamentals weak.

$LTHBearishMedium confidence
Context

Directors sold roughly $126M of LTH shares at $43.8 each, reflecting significant insider divestment after a 56% annual rally.

Expected impact

Potential short‑term downside.

Evidence & confidence

Sell size large relative to float; could signal concerns.

$RLAYBearishMedium confidence
Context

SVF Pauling (Cayman) Ltd sold 6M RLAY shares for $116.4M after a 426% price surge, indicating profit taking.

Expected impact

Short‑term price pressure expected.

Evidence & confidence

Large block sale after massive rally suggests valuation concerns.

$SNOWNeutralLow confidence
Context

Director Benoit Dageville sold 50,000 SNOW shares for $15.47M under a 10b5‑1 plan, reflecting routine liquidity.

Expected impact

Minimal price effect.

Evidence & confidence

Pre‑arranged plan; market likely priced in.

Market effects

Broad insider activity highlights heightened scrutiny in biotech and energy sectors.

U.S. market participants may adjust exposure to small‑cap biotech and oil stocks.

Limited; primarily affects U.S. listed micro‑cap equities.

Counterpoint

Insider sells may be routine liquidity events, not bearish signals.

Key entities

  • Neil S. Subin

    OPTU insider buyer

  • Gregory Austin Ciongoli

    RGNX insider buyer

  • Liane Rae Teplitsky

    PLSE insider buyer

  • Gary C. Evans

    UAMY insider buyer

  • William D. Rogers

    BATL insider buyer

Related articles

$SNOWMedAI 8/10

Snowflake Clears Melbourne IRAP, Backs $200M AI Bet

Snowflake achieved PROTECTED-level IRAP clearance for its Google Cloud deployment in Melbourne, joining AWS and Azure. The company also announced a $200M partnership with OpenAI. Snowflake reported Q2 FY2027 revenue of $1.55B, up 35% YoY, with product revenue at $1.49B, up 37% YoY. The company is positioning itself as a governed data layer for enterprise AI.

$SNOWMed

Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock

Insiders at Snowflake (SNOW), Palo Alto (PANW), Dell (DELL), GameStop (GME), and Crispr (CRSP) made notable trades. SNOW's CRO sold $253,951 in shares, PANW's director sold $7.5M, DELL saw multiple sales totaling $22.9M, GME's CEO bought $26.4M in shares, and CRSP's shareholder sold $780,934. These transactions may signal insider expectations.

$RGNXMedAI 8/10

Why is Regenxbio stock climbing today?

Regenxbio (RGNX) stock rose 3.5% in pre-market trading after presenting positive three-year data from its Phase II ALTITUDE study. 60% of participants showed clinically meaningful improvement, with no adverse events. Stifel maintained a Buy rating with a $42 price target. The broader market was modestly positive, but Regenxbio's pipeline developments drove the move.

$AKAMMed

Nasdaq, S&P 500 Futures Rise Despite Surging Treasury Yields: AMD, TSLA, SPCX, AKAM, BE Stocks In Focus

Nasdaq and S&P 500 futures rose despite surging Treasury yields. Akamai (AKAM) surged 20% after a $11.6B deal with Anthropic. Tesla (TSLA) trended upward following a next-gen Roadster unveil and Semi truck production news. SpaceX (SPCX) gained on AI model predictions. Bloom Energy (BE) rose 1% after reaffirming Oracle's (ORCL) fuel-cell contract. Comcast (CMCSA) fell on analyst downgrades. Regenxbio (RGNX) rose 2% on positive gene therapy data.

$RGNXMedAI 8/10

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

REGENXBIO (Nasdaq: RGNX) presented positive three-year data from its Phase II ALTITUDE study of surabgene lomparvovec for diabetic retinopathy at the Retina Society Annual Meeting. The data showed durable efficacy with 60% of participants achieving a >2-step improvement on the DRSS. No new safety signals were observed. The company is advancing the treatment in a Phase IIb/III trial.